Advanced search

  • Endokrynologia Polska
  • Vol 70, No 2 (2019) Recomendations on non-pharmacological interventions in women with PCOS to reduce body weight and improve metabolic disorders [Zalecenia dotyczące postępowania niefarmakologicznego u kobiet z PCOS celem zmniejszenia masy ciała i poprawy zaburzeń metabolicznych]
Vol 70, No 2 (2019)
Review paper
Published online: 2019-04-30

open access

View PDF Download PDF file
Page views 9023
Article views/downloads 6596
Get Citation

Connect on Social Media

Connect on Social Media

Recomendations on non-pharmacological interventions in women with PCOS to reduce body weight and improve metabolic disorders [Zalecenia dotyczące postępowania niefarmakologicznego u kobiet z PCOS celem zmniejszenia masy ciała i poprawy zaburzeń metabolicznych]

Anna Dutkowska1, Aleksandra Konieczna1, Justyna Breska-Kruszewska1, Magdalena Sendrakowska2, Irina Kowalska3, Dominik Rachoń4
DOI: 10.5603/EP.a2019.0006
Pubmed: 31039273
Endokrynol Pol 2019;70(2):198-212.

Abstract

Women with PCOS are characterised by ovarian hyperandrogenism, which, apart from fertility problems, hirsutism, acne, and androgenic alopecia, also leads to the development of central (android) obesity and its adverse metabolic consequences. Additionally, women with PCOS have intrinsic insulin resistance (IR) with its consequent hyperinsulinaemia, which leads to the development of atherosclerosis, arterial hypertension, and type 2 diabetes mellitus (T2DM), which give rise to cardiovascular disease (CVD), being the main cause of death among women. Although there are several publications on the topic of life-style changes in women with PCOS to normalise body weight and thus to reduce the adverse metabolic consequences of obesity, such as T2DM and CVD, the number of randomised studies that would enable the formation of strong recommendations is very limited. Nevertheless, taking into consideration the pathophysiology, any intervention implementing healthy dietary habits leading to the reduction of body weigh should be the core of non-pharmacological treatment in women with PCOS. The aim of the given recommendations herein is to point out and systemise the interventions on lifestyle change in women with PCOS as well as to form a practical guideline for the health care specialists, dieticians, and mental-therapists (psychologist) who take care of women with this syndrome.

Keywords: polycystic ovary syndromeobesityinsulin resistancelifestylediet

Article available in PDF format

View PDF Download PDF file

References

  1. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012; 97(1): 28–38.e25.
    CrossRefPubMed
  2. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016(2): 16057.
    CrossRefPubMed
  3. Pasquali R, Zanotti L, Fanelli F, et al. Defining hyperandrogenism in women with polycystic ovary syndrome: a challenging perspective. J Clin Endocrinol Metab. 2016; 101(5): 2013–2022.
    CrossRefPubMed
  4. Rachoń D, Teede H. Ovarian function and obesity — interrelationship, impact on women's reproductive lifespan and treatment options. Mol Cell Endocrinol. 2010; 316(2): 172–179.
    CrossRefPubMed
  5. Pasquali R, Gambineri A. Glucose intolerance states in women with the polycystic ovary syndrome. J Endocrinol Invest. 2013; 36(8): 648–653.
    CrossRefPubMed
  6. Gambineri A, Patton L, Altieri P, et al. Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes. 2012; 61(9): 2369–2374.
    CrossRefPubMed
  7. Papadakis G, Kandaraki E, Papalou O, et al. Is cardiovascular risk in women with PCOS a real risk? Current insights. Minerva Endocrinol. 2017; 42(4): 340–355.
    CrossRefPubMed
  8. Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012; 27(1): 14–24.
    CrossRefPubMed
  9. Azziz R, Carmina E, Dewailly D, et al. Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006; 91(11): 4237–4245.
    CrossRefPubMed
  10. Rachoń D. Differential diagnosis of hyperandrogenism in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2012; 120(4): 205–209.
    CrossRefPubMed
  11. Barry JA, Kuczmierczyk AR, Hardiman PJ. Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2011; 26(9): 2442–2451.
    CrossRefPubMed
  12. Press MJ, Howe R, Schoenbaum M, et al. Medicare Payment for Behavioral Health Integration. N Engl J Med. 2017; 376(5): 405–407.
    CrossRefPubMed
  13. Moran LJ, Pasquali R, Teede HJ, et al. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril. 2009; 92(6): 1966–1982.
    CrossRefPubMed
  14. Moran LJ, Hutchison SK, Norman RJ, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011(2): CD007506.
    CrossRefPubMed
  15. Lim SS, Davies MJ, Norman RJ, et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012; 18(6): 618–637.
    CrossRefPubMed
  16. Luque-Ramírez M, Escobar-Morreale HF. Polycystic ovary syndrome as a paradigm for prehypertension, prediabetes, and preobesity. Curr Hypertens Rep. 2014; 16(12): 500.
    CrossRefPubMed
  17. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab. 2003; 14(8): 365–370.
    PubMed
  18. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16): 1640–1645.
    CrossRefPubMed
  19. Ehrmann DA, Liljenquist DR, Kasza K, et al. PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91(1): 48–53.
    CrossRefPubMed
  20. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006; 91(2): 492–497.
    CrossRefPubMed
  21. Strowitzki T, Halser B, Demant T. Body fat distribution, insulin sensitivity, ovarian dysfunction and serum lipoproteins in patients with polycystic ovary syndrome. Gynecol Endocrinol. 2002; 16(1): 45–51.
    PubMed
  22. Amowitz LL, Sobel BE. Cardiovascular consequences of polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999; 28(2): 439–58, viii.
    PubMed
  23. Legro RS, Urbanek M, Kunselman AR, et al. Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated. Fertil Steril. 2002; 78(1): 51–57.
    PubMed
  24. Rogowicz-Frontczak A, Majchrzak A, Zozulińska-Ziółkiewicz D. Insulin resistance in endocrine disorders — treatment options. Endokrynol Pol. 2017; 68(3): 334–351.
    CrossRefPubMed
  25. Kowalska I, Straczkowski M, Nikolajuk A, et al. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod. 2007; 22(7): 1824–1829.
    CrossRefPubMed
  26. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012; 33(6): 981–1030.
    CrossRefPubMed
  27. Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999; 84(1): 165–169.
    CrossRefPubMed
  28. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999; 22(1): 141–146.
    PubMed
  29. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril. 2002; 77(6): 1095–1105.
    PubMed
  30. Hudecova M, Holte J, Olovsson M, et al. Diabetes and impaired glucose tolerance in patients with polycystic ovary syndrome — a long term follow-up. Hum Reprod. 2011; 26(6): 1462–1468.
    CrossRefPubMed
  31. Pelanis R, Mellembakken JR, Sundström-Poromaa I, et al. The prevalence of type 2 diabetes is not increased in normal-weight women with PCOS. Hum Reprod. 2017; 32(11): 2279–2286.
    CrossRefPubMed
  32. Moran LJ, Misso ML, Wild RA, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010; 16(4): 347–363.
    CrossRefPubMed
  33. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2017. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diab Prakt. 2017; 3(Suppl A): 1–82.
  34. Pirwany IR, Fleming R, Greer IA, et al. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clinical Endocrinology. 2001; 54(4): 447–453.
    CrossRefPubMed
  35. Valkenburg O, Steegers-Theunissen RPM, Smedts HPM, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab. 2008; 93(2): 470–476.
    CrossRefPubMed
  36. Brunzell JD, Ayyobi AF, et al. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med. 2003; 115(Suppl 8A): 24S–28S.
    PubMed
  37. Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 1995; 15(7): 821–826.
    PubMed
  38. Daan NMP, Louwers YV, Koster MPH, et al. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil Steril. 2014; 102(5): 1444–1451.e3.
    CrossRefPubMed
  39. Holte J, Gennarelli G, Berne C, et al. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod. 1996; 11(1): 23–28.
    PubMed
  40. Bentley-Lewis R, Seely E, Dunaif A. Ovarian hypertension: polycystic ovary syndrome. Endocrinol Metab Clin North Am. 2011; 40(2): 433–449, ix–x.
    CrossRefPubMed
  41. Vrbíková J, Cífková R, Jirkovská A, et al. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum Reprod. 2003; 18(5): 980–984.
    PubMed
  42. Lo JC, Feigenbaum SL, Yang J, et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91(4): 1357–1363.
    CrossRefPubMed
  43. Elting MW, Korsen TJ, Bezemer PD, et al. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod. 2001; 16(3): 556–560.
    PubMed
  44. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab. 2001; 86(1): 66–71.
    CrossRefPubMed
  45. Luque-Ramírez M, Alvarez-Blasco F, Mendieta-Azcona C, et al. Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2007; 92(6): 2141–2148.
    CrossRefPubMed
  46. Kargili A, Karakurt F, Kasapoglu B, et al. Association of polycystic ovary syndrome and a non-dipping blood pressure pattern in young women. Clinics (Sao Paulo). 2010; 65(5): 475–479.
    CrossRefPubMed
  47. Vgontzas AN, Legro RS, Bixler EO, et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab. 2001; 86(2): 517–520.
    CrossRefPubMed
  48. Morton A. Don't forget OSA with PCOS! BJOG. 2008; 115(1): 131–132.
    CrossRefPubMed
  49. Lansdown A, Rees DA. The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target? Clin Endocrinol (Oxf). 2012; 77(6): 791–801.
    CrossRefPubMed
  50. Macut D, Božić-Antić I, Bjekić-Macut J, et al. Management of endocrine disease: Polycystic ovary syndrome and nonalcoholic fatty liver disease. Eur J Endocrinol. 2017; 177(3): R145–R158.
    CrossRefPubMed
  51. Song DoK, Hong YS, Sung YA, et al. Insulin resistance according to β-cell function in women with polycystic ovary syndrome and normal glucose tolerance. PLoS One. 2017; 12(5): e0178120.
    CrossRefPubMed
  52. Frary JMC, Bjerre KP, Glintborg D, et al. The effect of dietary carbohydrates in women with polycystic ovary syndrome: a systematic review. Minerva Endocrinol. 2016; 41(1): 57–69.
    PubMed
  53. Gower BA, Chandler-Laney PC, Ovalle F, et al. Favourable metabolic effects of a eucaloric lower-carbohydrate diet in women with PCOS. Clin Endocrinol (Oxf). 2013; 79(4): 550–557.
    CrossRefPubMed
  54. Douglas CC, Gower BA, Darnell BE, et al. Role of diet in the treatment of polycystic ovary syndrome. Fertil Steril. 2006; 85(3): 679–688.
    CrossRefPubMed
  55. Gower BA, Goss AM. A lower-carbohydrate, higher-fat diet reduces abdominal and intermuscular fat and increases insulin sensitivity in adults at risk of type 2 diabetes. J Nutr. 2015; 145(1): 177S–183S.
    CrossRefPubMed
  56. Johansson-Persson A, Ulmius M, Cloetens L, et al. A high intake of dietary fiber influences C-reactive protein and fibrinogen, but not glucose and lipid metabolism, in mildly hypercholesterolemic subjects. Eur J Nutr. 2014; 53(1): 39–48.
    CrossRefPubMed
  57. Gomes JM, Fabrini SP, Alfenas RCG. Low glycemic index diet reduces body fat and attenuates inflammatory and metabolic responses in patients with type 2 diabetes. Arch Endocrinol Metab. 2017; 61(2): 137–144.
    CrossRefPubMed
  58. Marsh KA, Steinbeck KS, Atkinson FS, et al. Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome. Am J Clin Nutr. 2010; 92(1): 83–92.
    CrossRefPubMed
  59. Galletly C, Moran L, Noakes M, et al. Psychological benefits of a high-protein, low-carbohydrate diet in obese women with polycystic ovary syndrome — a pilot study. Appetite. 2007; 49(3): 590–593.
    CrossRefPubMed
  60. Moran LJ, Ko H, Misso M, et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J Acad Nutr Diet. 2013; 113(4): 520–545.
    CrossRefPubMed
  61. Harris WS. Are omega-3 fatty acids the most important nutritional modulators of coronary heart disease risk? Curr Atheroscler Rep. 2004; 6(6): 447–452.
    PubMed
  62. Mori TA, Beilin LJ, Burke V, et al. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol. 1997; 17(2): 279–286.
    PubMed
  63. Thies F, Garry JMC, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet. 2003; 361(9356): 477–485.
    CrossRefPubMed
  64. Heller A, Koch T, Schmeck J, et al. Lipid mediators in inflammatory disorders. Drugs. 1998; 55(4): 487–496.
    CrossRefPubMed
  65. Fleischhauer FJ, Yan WD, Fischell TA. Fish oil improves endothelium-dependent coronary vasodilation in heart transplant recipients. J Am Coll Cardiol. 1993; 21(4): 982–989.
    PubMed
  66. Nadjarzadeh A, Dehghani Firouzabadi R, Vaziri N, et al. The effect of omega-3 supplementation on androgen profile and menstrual status in women with polycystic ovary syndrome: A randomized clinical trial. Iran J Reprod Med. 2013; 11(8): 665–672.
    PubMed
  67. Rafraf M, Mohammadi E, Asghari-Jafarabadi M, et al. Omega-3 fatty acids improve glucose metabolism without effects on obesity values and serum visfatin levels in women with polycystic ovary syndrome. J Am Coll Nutr. 2012; 31(5): 361–368.
    PubMed
  68. Cussons AJ, Watts GF, Mori TA, et al. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab. 2009; 94(10): 3842–3848.
    CrossRefPubMed
  69. Barbosa MM, Melo AL, Damasceno NR. The benefits of omega-3 supplementation depend on adiponectin basal level and adiponectin increase after the supplementation: A randomized clinical trial. Nutrition. 2017; 34: 7–13.
    CrossRefPubMed
  70. Sirbu AE, Buburuzan L, Kevorkian S, et al. Adiponectin expression in visceral adiposity is an important determinant of insulin resistance in morbid obesity. Endokrynol Pol. 2018; 69(3): 252–258.
    CrossRefPubMed
  71. Hajishafiee M, Askari G, Iranj B, et al. The Effect of n-3 Polyunsaturated Fatty Acid Supplementation on Androgen Status in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Clinical Trials. Horm Metab Res. 2016; 48(5): 281–289.
    CrossRefPubMed
  72. Phelan N, O'Connor A, Kyaw Tun T, et al. Hormonal and metabolic effects of polyunsaturated fatty acids in young women with polycystic ovary syndrome: results from a cross-sectional analysis and a randomized, placebo-controlled, crossover trial. Am J Clin Nutr. 2011; 93(3): 652–662.
    CrossRefPubMed
  73. Whelan J, Rust C. Innovative dietary sources of n-3 fatty acids. Annu Rev Nutr. 2006; 26: 75–103.
    CrossRefPubMed
  74. Kris-Etherton PM, Harris WS, Appel LJ, et al. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2003; 22(2): e20–e30.
    PubMed
  75. Ott C, Jacobs K, Haucke E, et al. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014; 2: 411–429.
    CrossRefPubMed
  76. Garg D, Merhi Z. Advanced Glycation End Products: Link between Diet and Ovulatory Dysfunction in PCOS? Nutrients. 2015; 7(12): 10129–10144.
    CrossRefPubMed
  77. Tantalaki E, Piperi C, Livadas S, et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones (Athens). 2014; 13(1): 65–73.
    PubMed
  78. Lin AW, Lujan ME. Comparison of dietary intake and physical activity between women with and without polycystic ovary syndrome: a review. Adv Nutr. 2014; 5(5): 486–496.
    PubMed
  79. Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. Metabolism. 2018; 86: 33–43.
    CrossRefPubMed
  80. Scott D, Harrison CL, Hutchison S, et al. Exploring factors related to changes in body composition, insulin sensitivity and aerobic capacity in response to a 12-week exercise intervention in overweight and obese women with and without polycystic ovary syndrome. PLoS One. 2017; 12(8): e0182412.
    CrossRefPubMed
  81. Malcolm G, Rilstone S, Sivasubramaniyam S, et al. Managing diabetes at high altitude: personal experience with support from a Multidisciplinary Physical Activity and Diabetes Clinic. BMJ Open Sport Exerc Med. 2017; 3(1): e000238.
    CrossRefPubMed
  82. Kim JC. The effect of exercise training combined with PPARγ agonist on skeletal muscle glucose uptake and insulin sensitivity in induced diabetic obese Zucker rats. J Exerc Nutrition Biochem. 2016; 20(2): 42–50.
    CrossRefPubMed
  83. Haqq L, McFarlane J, Dieberg G, et al. The Effect of Lifestyle Intervention on Body Composition, Glycemic Control, and Cardiorespiratory Fitness in Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis. Int J Sport Nutr Exerc Metab. 2015; 25(6): 533–540.
    CrossRefPubMed
  84. Parker L, Shaw CS, Banting L, et al. Acute Low-Volume High-Intensity Interval Exercise and Continuous Moderate-Intensity Exercise Elicit a Similar Improvement in 24-h Glycemic Control in Overweight and Obese Adults. Front Physiol. 2016; 7: 661.
    CrossRefPubMed
  85. Nybacka Å, Carlström K, Ståhle A, et al. Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome. Fertil Steril. 2011; 96(6): 1508–1513.
    CrossRefPubMed
  86. Brennan L, Teede H, Skouteris H, et al. Lifestyle and Behavioral Management of Polycystic Ovary Syndrome. J Womens Health (Larchmt). 2017; 26(8): 836–848.
    CrossRefPubMed
  87. Mahalingaiah S, Diamanti-Kandarakis E. Targets to treat metabolic syndrome in polycystic ovary syndrome. Expert Opin Ther Targets. 2015; 19(11): 1561–1574.
    CrossRefPubMed
  88. Cooney LG, Lee I, Sammel MD, et al. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017; 32(5): 1075–1091.
    CrossRefPubMed
  89. Jones GL, Hall JM, Lashen HL, et al. Health-related quality of life among adolescents with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs. 2011; 40(5): 577–588.
    CrossRefPubMed
  90. McCook JG, Reame NE, Thatcher SS. Health-related quality of life issues in women with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs. 2005; 34(1): 12–20.
    CrossRefPubMed
  91. Hahn S, Janssen OE, Tan S, et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol. 2005; 153(6): 853–860.
    CrossRefPubMed
  92. Colwell K, Lujan ME, Lawson KL, et al. Women's perceptions of polycystic ovary syndrome following participation in a clinical research study: implications for knowledge, feelings, and daily health practices. J Obstet Gynaecol Can. 2010; 32(5): 453–459.
    CrossRefPubMed
  93. Banting LK, Gibson-Helm M, Polman R, et al. Physical activity and mental health in women with polycystic ovary syndrome. BMC Womens Health. 2014; 14(1): 51.
    CrossRefPubMed
  94. Correa JB, Sperry SL, Darkes J. A case report demonstrating the efficacy of a comprehensive cognitive-behavioral therapy approach for treating anxiety, depression, and problematic eating in polycystic ovarian syndrome. Arch Womens Ment Health. 2015; 18(4): 649–654.
    CrossRefPubMed
  95. Raja-Khan N, Agito K, Shah J, et al. Mindfulness-based stress reduction for overweight/obese women with and without polycystic ovary syndrome: design and methods of a pilot randomized controlled trial. Contemp Clin Trials. 2015; 41: 287–297.
    CrossRefPubMed
  96. Geier LM, Bekx MT, Connor EL. Factors contributing to initial weight loss among adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2012; 25(6): 367–370.
    CrossRefPubMed
  97. Muscogiuri G, Altieri B, de Angelis C, et al. Shedding new light on female fertility: The role of vitamin D. Rev Endocr Metab Disord. 2017; 18(3): 273–283.
    CrossRefPubMed
  98. Sewerynek E, Cieślak K, Janik M, et al. Evaluation of vitamin D concentration in a population of young, healthy women - the effects of vitamin D supplementation. Endokrynol Pol. 2017; 68(5): 533–540.
    CrossRefPubMed
  99. Munns CF, Shaw N, Kiely M, et al. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J Clin Endocrinol Metab. 2016; 101(2): 394–415.
    CrossRefPubMed
  100. Jakimiuk AJ, Szamatowicz J. Rola niedoboru inozytolu w patofizjologii zaburzeń występujących w zespole policystycznych jajników [The role of inositol deficiency in the etiology of polycystic ovary syndrome disorders]. Ginekol Pol. 2014; 85(1): 54–57.
    PubMed
  101. Unfer V, Nestler JE, Kamenov ZA, et al. Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials. Int J Endocrinol. 2016; 2016(1849162).
    CrossRefPubMed
  102. Garg D, Tal R. Inositol Treatment and ART Outcomes in Women with PCOS. Int J Endocrinol. 2016; 2016: 1979654.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note